FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Alfredo Falcone, Alberto Zaniboni et al.|The Lancet Oncology|2015Cited by 1.1k
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Filippo Pietrantonio, Vincenzo Guarini et al.|British Journal of Cancer|2020Cited by 350
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al.|The Lancet Oncology|2020Cited by 322
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Chiara Cremolini, Daniele Rossini et al.|The Lancet Oncology|2022Cited by 268
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal CancerMarinde J. G. Bond, Johannes J.M. Kwakman, Maarten van Smeden et al.|JCO Clinical Cancer Informatics|2024Cited by 6